Literature DB >> 14574328

Post-transcriptional regulation of inducible nitric oxide synthase in chronic lymphocytic leukemia B cells in pro- and antiapoptotic culture conditions.

A C Tiscornia1, A Cayota, A I Landoni, C Brito, P Oppezzo, F Vuillier, C Robello, G Dighiero, R Gabús, O Pritsch.   

Abstract

Functional inducible NOS (iNOS) may be involved in the prolonged lifespan of chronic lymphocytic leukemia cells (B-CLL), although the exact mechanisms implicated remain elusive as yet. In this work, we have examined iNOS expression in normal B lymphocytes and B-CLL cells in pro- and antiapoptotic conditions. Our results demonstrate: (1) The existence of a new splice variant characterized by a complete deletion of exon 14 (iNOS 13-16(14del)), which was preferentially detected in normal B lymphocytes and may represent an isoform that could play a role in the regulation of enzyme activity. (2) The existence of another alternatively spliced iNOS mRNA transcript involving a partial deletion of the flavodoxin region (iNOS 13-16(neg)) was correlated to a decreased B-CLL cell viability. The 9-beta-D-arabinofuranosyl-2-fluoradenine or fludarabine (F-ara) treatment induced iNOS 13-16(neg) transcript variants, whereas IL-4 enhanced both the transcription of variants, including these exons (iNOS 13-16(pos)), and the expression of a 122 kDa iNOS protein. These results suggest that in B-CLL, a regulation process involving nitric oxide (.- NO) levels could occur by a post-transcriptional mechanism mediated by soluble factors. Our results also provide an insight into a new complementary proapoptotic action of F-ara in B-CLL by the induction of particular iNOS splice variants, leading to the activation of a caspase-3-dependent apoptotic pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14574328     DOI: 10.1038/sj.leu.2403169

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

1.  Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients.

Authors:  Eleni Arvaniti; Stavroula Ntoufa; Nikos Papakonstantinou; Tasoula Touloumenidou; Nikolaos Laoutaris; Achilles Anagnostopoulos; Klea Lamnissou; Federico Caligaris-Cappio; Kostas Stamatopoulos; Paolo Ghia; Marta Muzio; Chrysoula Belessi
Journal:  Haematologica       Date:  2011-07-12       Impact factor: 9.941

2.  Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2.

Authors:  Christine E Eyler; Qiulian Wu; Kenneth Yan; Jennifer M MacSwords; Devin Chandler-Militello; Katherine L Misuraca; Justin D Lathia; Michael T Forrester; Jeongwu Lee; Jonathan S Stamler; Steven A Goldman; Markus Bredel; Roger E McLendon; Andrew E Sloan; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cell       Date:  2011-07-08       Impact factor: 41.582

3.  NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism.

Authors:  Haifeng Zhu; Deeksha Vishwamitra; Choladda V Curry; Roxsan Manshouri; Lixia Diao; Aarish Khan; Hesham M Amin
Journal:  J Pathol       Date:  2013-03-14       Impact factor: 7.996

Review 4.  Molecular Mechanisms of Nitric Oxide in Cancer Progression, Signal Transduction, and Metabolism.

Authors:  Veena Somasundaram; Debashree Basudhar; Gaurav Bharadwaj; Jae Hong No; Lisa A Ridnour; Robert Y S Cheng; Mayumi Fujita; Douglas D Thomas; Stephen K Anderson; Daniel W McVicar; David A Wink
Journal:  Antioxid Redox Signal       Date:  2018-05-02       Impact factor: 8.401

Review 5.  Abnormalities in alternative splicing of angiogenesis-related genes and their role in HIV-related cancers.

Authors:  Nonkululeko N Mthembu; Zukile Mbita; Rodney Hull; Zodwa Dlamini
Journal:  HIV AIDS (Auckl)       Date:  2017-03-30

6.  Physarum nitric oxide synthases: genomic structures and enzymology of recombinant proteins.

Authors:  Simon Messner; Stephan Leitner; Christian Bommassar; Georg Golderer; Peter Gröbner; Ernst R Werner; Gabriele Werner-Felmayer
Journal:  Biochem J       Date:  2009-03-15       Impact factor: 3.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.